Hepatology

Papers
(The H4-Index of Hepatology is 76. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)
ArticleCitations
Epidemiology of Hepatocellular Carcinoma1151
The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review775
AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease696
A multisociety Delphi consensus statement on new fatty liver disease nomenclature610
Diagnosis, Evaluation, and Management of Ascites, Spontaneous Bacterial Peritonitis and Hepatorenal Syndrome: 2021 Practice Guidance by the American Association for the Study of Liver Diseases389
Vascular Liver Disorders, Portal Vein Thrombosis, and Procedural Bleeding in Patients With Liver Disease: 2020 Practice Guidance by the American Association for the Study of Liver Diseases352
Malnutrition, Frailty, and Sarcopenia in Patients With Cirrhosis: 2021 Practice Guidance by the American Association for the Study of Liver Diseases336
AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma332
From NAFLD to MAFLD: Implications of a Premature Change in Terminology270
Yttrium‐90 Radioembolization for the Treatment of Solitary, Unresectable HCC: The LEGACY Study268
Hepatic fibrosis 2022: Unmet needs and a blueprint for the future241
Multiple Parallel Hits Hypothesis in Nonalcoholic Fatty Liver Disease: Revisited After a Decade220
Detection of Circulating Tumor Cells and Their Implications as a Biomarker for Diagnosis, Prognostication, and Therapeutic Monitoring in Hepatocellular Carcinoma213
Saroglitazar, a PPAR‐α/γ Agonist, for Treatment of NAFLD: A Randomized Controlled Double‐Blind Phase 2 Trial209
Predicting Survival After Hepatocellular Carcinoma Resection Using Deep Learning on Histological Slides180
Cancer‐Associated Fibroblast‐Mediated Cellular Crosstalk Supports Hepatocellular Carcinoma Progression175
Combination Therapies Including Cilofexor and Firsocostat for Bridging Fibrosis and Cirrhosis Attributable to NASH173
Use of Hepatocellular Carcinoma Surveillance in Patients With Cirrhosis: A Systematic Review and Meta‐Analysis173
Lenvatinib Targets FGF Receptor 4 to Enhance Antitumor Immune Response of Anti–Programmed Cell Death‐1 in HCC171
The liver cancer immune microenvironment: Therapeutic implications for hepatocellular carcinoma160
Population screening for liver fibrosis: Toward early diagnosis and intervention for chronic liver diseases148
Insights into modifiable risk factors of cholelithiasis: A Mendelian randomization study147
A Randomized Clinical Trial of Fecal Microbiota Transplant for Alcohol Use Disorder142
Liver Biochemistries in Hospitalized Patients With COVID‐19142
High‐quality diet, physical activity, and college education are associated with low risk of NAFLD among the US population142
Administrative Coding in Electronic Health Care Record‐Based Research of NAFLD: An Expert Panel Consensus Statement138
Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child‐Pugh A and B cirrhosis: A real‐world study133
Emerging immunotherapy for HCC: A guide for hepatologists125
A Machine Learning Approach Enables Quantitative Measurement of Liver Histology and Disease Monitoring in NASH125
Retracted: M2 Macrophage–Derived Exosomes Facilitate HCC Metastasis by Transferring αMβ2 Integrin to Tumor Cells123
The Tumor Microenvironment in Cholangiocarcinoma Progression117
Myeloid‐Cell–Specific IL‐6 Signaling Promotes MicroRNA‐223‐Enriched Exosome Production to Attenuate NAFLD‐Associated Fibrosis116
Compromised hepatic mitochondrial fatty acid oxidation and reduced markers of mitochondrial turnover in human NAFLD115
Microbiota‐Driven Activation of Intrahepatic B Cells Aggravates NASH Through Innate and Adaptive Signaling115
American Association for the Study of Liver Diseases Expert Panel Consensus Statement: Vaccines to Prevent Coronavirus Disease 2019 Infection in Patients With Liver Disease114
Application of Artificial Intelligence for the Diagnosis and Treatment of Liver Diseases113
Iron Chaperone Poly rC Binding Protein 1 Protects Mouse Liver From Lipid Peroxidation and Steatosis113
Cancer Risk in Patients With Biopsy‐Confirmed Nonalcoholic Fatty Liver Disease: A Population‐Based Cohort Study111
A Circular RNA, Cholangiocarcinoma‐Associated Circular RNA 1, Contributes to Cholangiocarcinoma Progression, Induces Angiogenesis, and Disrupts Vascular Endothelial Barriers111
Biomarkers for Hepatobiliary Cancers107
Surgical Treatments of Hepatobiliary Cancers106
Immunomodulatory Effects of Lenvatinib Plus Anti–Programmed Cell Death Protein 1 in Mice and Rationale for Patient Enrichment in Hepatocellular Carcinoma105
Global burden of NAFLD and chronic liver disease among adolescents and young adults104
HBV‐Induced Increased N6 Methyladenosine Modification of PTEN RNA Affects Innate Immunity and Contributes to HCC100
Risk Prediction Models for Post‐Operative Mortality in Patients With Cirrhosis99
CAFs shape myeloid‐derived suppressor cells to promote stemness of intrahepatic cholangiocarcinoma through 5‐lipoxygenase99
Osteopontin Takes Center Stage in Chronic Liver Disease99
The associations between modifiable risk factors and nonalcoholic fatty liver disease: A comprehensive Mendelian randomization study98
Single‐Cell Transcriptomic Analysis Reveals a Hepatic Stellate Cell–Activation Roadmap and Myofibroblast Origin During Liver Fibrosis in Mice98
Are there outcome differences between NAFLD and metabolic‐associated fatty liver disease?97
NAFLD: Reporting Histologic Findings in Clinical Practice96
AASLD practice guidance on primary sclerosing cholangitis and cholangiocarcinoma96
PPARγ Coactivator‐1α Suppresses Metastasis of Hepatocellular Carcinoma by Inhibiting Warburg Effect by PPARγ–Dependent WNT/β‐Catenin/Pyruvate Dehydrogenase Kinase Isozyme 1 Axis95
IL‐1β‐Induced Elevation of Solute Carrier Family 7 Member 11 Promotes Hepatocellular Carcinoma Metastasis Through Up‐regulating Programmed Death Ligand 1 and Colony‐Stimulating Factor 194
Endoplasmic reticulum stress in liver diseases93
Hypoxia‐driven immunosuppression by Treg and type‐2 conventional dendritic cells in HCC93
Reply: A multi-society Delphi consensus statement on new fatty liver disease nomenclature93
Sirt6 Alleviated Liver Fibrosis by Deacetylating Conserved Lysine 54 on Smad2 in Hepatic Stellate Cells93
Genetic Determinants of Outcome in Intrahepatic Cholangiocarcinoma92
A Systematic Review of Animal Models of NAFLD Finds High‐Fat, High‐Fructose Diets Most Closely Resemble Human NAFLD91
Transcriptomics Identify Thrombospondin‐2 as a Biomarker for NASH and Advanced Liver Fibrosis90
Lipid Remodeling in Hepatocyte Proliferation and Hepatocellular Carcinoma89
GALAD demonstrates high sensitivity for HCC surveillance in a cohort of patients with cirrhosis89
NAFLD‐related hepatocellular carcinoma: The growing challenge87
AASLD Practice Guidance: Palliative care and symptom‐based management in decompensated cirrhosis87
Getting to HBV cure: The promising paths forward87
Role of the Mammalian Target of Rapamycin Pathway in Liver Cancer: From Molecular Genetics to Targeted Therapies86
Hypoxia‐Inducible Exosomes Facilitate Liver‐Tropic Premetastatic Niche in Colorectal Cancer85
Tenofovir Versus Entecavir on Recurrence of Hepatitis B Virus–Related Hepatocellular Carcinoma After Surgical Resection85
Cordycepin Ameliorates Nonalcoholic Steatohepatitis by Activation of the AMP‐Activated Protein Kinase Signaling Pathway81
The Use of Rifaximin in Patients With Cirrhosis80
Impact of COVID‐19 Pandemic on Liver Transplantation and Alcohol‐Associated Liver Disease in the USA80
Heterogeneity of HSCs in a Mouse Model of NASH80
Local and Regional Therapies for Hepatocellular Carcinoma80
Reducing the Global Burden of Alcohol‐Associated Liver Disease: A Blueprint for Action79
Extracellular vesicles derived from mesenchymal stem/stromal cells: The regenerative impact in liver diseases78
An Updated Assessment of Chronic Hepatitis B Prevalence Among Foreign‐Born Persons Living in the United States76
0.054220914840698